Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data
One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.
One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.